It is well documented that the large gap in breast cancer survival between black and white women began in the 1980s, following the introduction of adjuvant endocrine therapy for ER+ breast cancer status and continued with subsequent therapies for PR+ and HER2+ subtypes[67]. The gene discussed is ESR1; the disease is breast carcinoma.